Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 6, 2005 - Issue 12
Submit an article Journal homepage
112
Views
19
CrossRef citations to date
0
Altmetric
Review

Pharmacogenomics in lung cancer: an analysis of DNA repair gene expression in patients treated with platinum-based chemotherapy

Rosario García-Campelo Medical Oncology Service, Hospital Juan Canalejo, As Xubias, 84, 15006, A Coruña, Spain. [email protected]
,
Guillermo Alonso-Curbera Medical Oncology Service, Hospital Juan Canalejo, As Xubias, 84, 15006, A Coruña, Spain. [email protected]
,
LM Antón Aparicio Medical Oncology Service, Hospital Juan Canalejo, As Xubias, 84, 15006, A Coruña, Spain. [email protected]
&
Rafael Rosell Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona (Barcelona), Spain
Pages 2015-2026 | Published online: 03 Oct 2005

Bibliography

  • JEMAL A, MURRAY T, WARD E et aL: Cancer Statistics, 2005. CA Cancerj Clin. (2005) 55:10–30.
  • BELANI CP, LANGER C: First-line chemotherapy for NSCLC: an overview of relevant trials. Lung Cancer(2002) 38(4):13–19.
  • SCHILLER JH, HARRINGTON D, BELANI CP et al.: Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N EngL J. Med. (2002) 346:92–98.
  • SCAGLIOTTI G, DE MARINIS F, RINALDI M et al.: Phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer. J. Clin. OncoL (2002) 20:4285–4291.
  • MARSHALL A: Laying the foundations for personalized medicine. Nat. BiotechnoL (1997) 16:954–957.
  • ZAMORANO PL, MAHESH VB, BRANN DW: Quantitative RT-PCR for neuroendocrine studies. A minireview. Neuroendocrinology (1996) 63:397–407
  • GINZINGER D: Gene quantification using real-time quantitative PCR: an emerging technology hits the mainstream. Exp. HematoL (2002) 30:503–512.
  • ••Complete description of an emergingtechnique: RT-QPCR.
  • JAQUECT R, HILLYER J, LANDIS WJ: Analysis of connective tissues by laser capture microdissection and reverse transcriptase-polymerase chain reaction. Anal. Biochem. (2005) 337:22–34.
  • FINK L, SEEGER W, ERMERT Let al.: Real-time quantitative RT-PCR after laser-assisted cell picking. Nat. Med. (1998) 4:1329–1333.
  • LOS G, YANG F, SAMINI G et al.: Using mRNA expression profiling to determine anticancer drug efficacy. Cytometry (2002) 47:66–71.
  • PHILLIPS DH: The formation of DNA adducts. The cancer handbook. Nature Publishing Group, London (2002):293–307.
  • WEI Q, CHENG L, HONG WK, SPITZ MR: Reduced DNA repair capacity in lung cancer patients. Cancer Res. (1996) 90:1614–1618.
  • WEI Q, CHENG L, AMOS CI et aL: Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiological study. J. NatL Cancer Inst. (2000) 92:1764–1772
  • BOSKEN CH, WEI Q, AMOS CI, SPITZ MR: An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer. NatL Cancer Inst. (2002) 94:1091–1099.
  • •An analysis of NER activity estimated as DRC in survival of NSCLC patients.
  • WOOD RD, MITCHELL M, SGOUROS J, LINDAHL T: Human DNArepair genes. Science (2001) 291:1284–1289
  • ••A comprehensive review of human DNArepair genes and the different pathways of repair.
  • REED E: Platinum-DNA adduct, nucleotide excision repair and platinum based anticancer chemotherapy. Cancer Treat. Rev. (1998) 24:331–344.
  • DE BOER J, HOEIJMAKERS JH: Nucleotide excision repair and human syndromes. Carcinogenesis (2000) 21:453–460.
  • HOUTSMULLER AB, RADEMAKERS S, NIGG AL, HOOGSTRATEN D, HOEIJMAKERS JH, VERMEULEN W: Action of DNA repair endonuclease ERCC1/XPF in living cells. Science (1999) 284:958–961.
  • LI Q, YU JJ, MU C et al.: Association between the level of ERCC1 expression and the repair of cisplatin-induced DNA damage in ovarian cancer cells. Anti-Cancer Res. (2000) 20(2A):645–652.
  • SIMON GR, SHARMA S, CANTOR A, SMITH P, BEPLER G: ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest (2005) 127:978–983.
  • ••One of the first reported data regardingERCC1 expression as a predictor of survival in resected NSCLC patients.
  • METZGER R, LEICHMAN CG, DANENBERG KD et aL: ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J. Clin. OncoL (1998) 16:309–316.
  • DABHOLKAR M, BOSTICK- BRUTON F, WEBER C et al.: ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J. NatL Cancer Inst. (1992) 84:1512–1517.
  • WARNECKE-EBERZ U, METZGER R MIYAZONO F et al.: High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer. Clin. Cancer Res. (2004) 10:3794–3799.
  • SHIROTA Y, STOEHLMACHER J, BRABENDER J et al.: ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J. Clin. Oncol. (2001) 19:4298–4304.
  • YANG LY, LI L, PAN H, SHEN Y, PLUNKETT W: Expression of ERCC1 antisense RNA abrogates gemcitabine-mediated cytotoxic synergism with cisplatin in human colon tumour cells defective in mismatch repair but proficient in nucleotide excision repair. Clin. Cancer Res. (2000) 6:773–781.
  • •Interesting data proving the value of ERCC1 for CDDP/gemcitabine synergism.
  • LORD R, BRABENDER J, GANDARA D et al.: Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin. Cancer Res. (2002) 8:2286–2291.
  • ••A preliminary study of the SLCG showingan association between lower ERCC1 expression and improved survival after CDDP/gemcitabine treatment.
  • ROSELL R, DANENBERG KD, ALBEROLA Vet al.: Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin. Cancer Res. (2004) 10:1318–1325.
  • ROSELL R, COBO M, ISLA I et al.: ERCC1 mRNA-based randomized Phase III trial of docetaxel doublets with cisplatin or gemcitabine in stage IV non-small-cell lung cancer. Proc. Am. Soc. Clin. Oncol. (2005):Abstr. 7002.
  • HOEIJMAKERS JH, EGLY JM, VERMEULEN W: TFHIIH: a key component in multiple DNA transactions. Curr. Opin. Genet. Dev. (1996) 6:26–33.
  • EVENO E, BOURRE F, QUILLIET X et al.: Different removal of ultraviolet photoproducts in genetically related xeroderma pigmentosum and trichothiodystrophy diseases. Cancer Res. (1995) 5:4325–4332.
  • FURUTA T, UEDA T, AUNE G et al.: Transcription- coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res. (2002) 62:4899–4902.
  • VOGEL U, DYBDAHL M, FRENTZ G, NEXO BA: DNA repair capacity: inconsistency between effect of overexpression of five NER genes and the correlation to mRNA levels in primary lymphocytes. Mutat. Res. (2000) 461:197–210.
  • ALOYZ R, XU ZY, BELLO Vet al.: Regulation of cisplatin resistance and homologous recombinational repair by TFIIH subunit XPD. Cancer Res. (2002) 62:5457–5462.
  • ARMELINI M, MUOTRI A, MARCHETOO AC et aL: Restoring DNA repair capacity of cells from three distinct diseases by XPD gene-recombinant adenovirus. Cancer Gene Ther. (2005) 4:389–396.
  • ELLEDGE SJ, ZHOU Z, ALLEN JB: Ribonucleotide reductase: regulation, regulation, regulation. Trends Biochem. Sci.(1992) 17:119–23.
  • JORDAN A, REICHAR P: Ribonucleotide reductase. Annu. Rev. Biochem. (1998) 67:71–98.
  • ZHOU B, LIU X, MO X et al.: The human ribonucleotide reductase subunit hRRM2 complements p53R2 in response to UV-induced DNA repair in cells with mutant p53. Cancer Res. (2003) 63(20):6583–6594.
  • PITTERLE DM, KIM YC, JOLICOEUR EMC, GAO Y, 0 'BRIANT K, BEPLER G: Lung cancer and the human gene for ribonucleotide reductase subunit M1 (RRM1). Mamm. Genome (1999) 10:916–922
  • BEPLER G, GAUTAM A. MCINTYRE LM et al.: Prognostic significance of molecular genetic aberrations on chromosome segment 11p15.5 in non-small-cell lung cancer. J. Clin. Oncol. (2002) 20:1353–1360.
  • GAUTAM A, LI ZR, BEPLER G: RRM1 induced metastasis suppression through PTEN-regulated pathways. Oncogene (2003) 22:2135–2142.
  • •An interesting review of the different roles of R12.1\41 and its interaction with the tumour suppresor gene PTEN.
  • HUANG P, CHUBB S, HERTEL LW, GRINDEY GB, PLUNKETT W: Action of 2'2'-Difluorodeoxycytidine on DNA synthesis. Cancer Res. (1991) 51(22):6110–6117.
  • BAKER CH, BANZON J, BOLLINGER JM: 2'-deoxy-2'2-methylenecytidine and 2'-deoxy-2',2'-difluorocytidine5'-diphosphates: potent mechanism-based inhibitors of ribonucleotide reductase. J. Med. Chem (1991) 34(6):1879–1884.
  • GOAN YG, ZHOU B, HUE, MIS, YEN Y: Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line. Cancer Res. (1999) 59:4204–4207.
  • DUMONTET C, FABIANOWSKA-MAJEWSDA K, MANTINCIC D et al.: Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562. Br. J. Haematol. (1999) 106:78–85
  • DAVIDSON J, MA L, FLAGELLA M, GEEGANAGE S, GELBERT LM, SLAPAK CA: An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res. (2004) 64(11):3761–3766.
  • BEPLER G, SHARMA S, CANTOR A et al.: RRM1 and PTEN as prognostic parameters for overall survival and disease-free survival in patients with non-small cell lung cancer. J. Clin. Oncol. a(2004) 22:1878–1885
  • ROSELL R, SCAGLIOTTI G, DANENBER KD et al.: Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene (2003) 22:3548–3553.
  • ••Retrospective study showing the value ofRR1V11 expression as a molecular marker of chemotherapy response.
  • ALBEROLA V, CAMPS C, PROVENCIO M et al.: Cisplatin plus gemcitabine versus a cisplatin-based triplet versus non-platinum sequential doublets in advanced non-small cell lung cancer: a Spanish Lung Cancer Group Phase III randomized trial. J. Clin. Oncol. a(2003) 21:3207–3213.
  • ROSELL R, FELIP E, TARON M et al.: Gene expression as a predictive marker of outcome in stage IIB-IIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Clin. Cancer Res. (2004) 10:4215–4219.
  • MIKI Y, SWENSEN J, SHATTUCK-EIDENS D: A strong candidate for the breast and ovarian cancer susceptibility gene, BRCA1. Science (1994) 266:66–71.
  • KENNEDY RD, QUINN JE, JOHNSTON PG, HARKIN DP: BRCA1: mechanisms of inactivation and implications for management of patients. Lancet (2002) 360:1007–1014.
  • ••A complete review of BRCA1 functions,focused on BRCA1 mutation.
  • THOMPSON ME, JENSEN RA, OBERMILLER PS, PAGE DL, HOLT JT: Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat. Genet. (1995) 9(4):444–50.
  • SEERTY LT, KNOWLDEN JM, GEE JM et al.: BRCA1 expression level predict distant metastasis of sporadic breast cancers. Int. J. Cancer (1999) 84:258–262.
  • RICE J, OZCELIK H, MAXEINER P, ANDRULIS I, FUTSCHER BW: Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens. Carcinogenesis (2000) 21(9):1761–1765.
  • MARSIT CJ, LIU M, NELSON HH, POSNER M, SUZUKI M, ELSEY KT: Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival. Oncogene (2004) 23:1000–1004.
  • TANIGUCHI T, TISCHKOWITZ M, AMEZIANE N et al.: Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumours. Nat. Med. (2003) 9:568–574.
  • THOMPSON LH, SCHILD D: Homologous recombinational repair of DNA ensures mammalian chromosome stability. Mutat. Res. (2001) 477:131–153.
  • GOWEN LC, AVRUTSKAYA AV, LATOUR AM, DOLLER BH, LEADON SA: BRCA1 required for transcription-coupled repair of oxidative DNA damage. Science (1998) 281:1009–1012.
  • WANG Y, CORTEZ D, YAZDI P, NEFF N, ELLEDGE SJ, QIN J: BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of DNA structures. Genes Dev. (2000) 14:927–939.
  • CORTEZ D, WANG Y, QIN J, ELLEDGE SJ: Requirement of ATM-dependent phosphorylation of BRCA1 in DNA damage response to double-strand breaks. Science (1999) 286:1162–1166.
  • LEE JS, COLLINS KM, BROWN AL, LEE CH, CHUNG JH: hCdsl-mediated phosphorylation of BRCA1 regulates the DNA damage response. Nature (2000) 404:201–204.
  • HSU LC, WHITE RL: BRCA1 is associated with the centrosome during the mitosis. Proc. NatL Acad. Sci. USA (1998) 95(22):12983–12988.
  • HARKIN DP, BEAN JM, MIKLOS D et al.: Induction of GADD45 and JNK/ SAPK-dependent apoptosis following inducible expression of BRCA1. Cell (1999) 97:575–586.
  • POTAPOVA 0, HAGHIGHI A, BOST F et al.: The Jun kinase/stress-activated protein kinase pathway functions to regulate DNA repair and inhibition of the pathway sensitizes tumour cells to cisplatin. Biol. Chem. (1997) 272(22):14041–14044.
  • LAFARGE S, SYLVAIN V, FERRARA M, BIGNON YJ: Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. Oncogene (2001) 20:6597–6606.
  • HUSAIN A, HE G, VENKATRAMAN ES, SPRIGSS DR: BRCA1 upregulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum. Cancer Res. (1998) 58:1120–1123.
  • MULLAN PB, QUINN JE, GILMORE PM et al.: BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents. Oncogene (2001) 20:6123–6131.
  • EGAWA C, MIYOSHI Y, TAKAMURA Y, TAGUCHI T, TAMAKI Y, NOGUCHI S: Decreased expression of BRCA2 mRNA predicts favorable response to docetaxel in breast cancer. Int. J. Cancer (2001) 95:255–259.
  • TARON M, ROSELL R, FELIP E et al.: BRCA1 mRNA expression levels as an indicator of chemoresistance. Lung Cancer Hum. MoL Genet. (2004) 20:2443–2449.
  • ••One of the first clinical studies reportingthe role of BRCA1 expression as a predictive marker of chemotherapy response in lung cancer.

Website

  • www.nih.gov/sigs/dna-rep/whatis.html Overview of mammalian DNA repair systems. Accessed 15 August, 2005.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.